Title: A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy
Authors: Pignata, S ×
Amant, Frédéric
Scambia, G
Sorio, R
Breda, E
Rasch, W
Hernes, K
Pisano, C
Leunen, K
Lorusso, D
Cannella, L
Vergote, Ignace #
Issue Date: Nov-2011
Publisher: Springer-Verlag
Series Title: Cancer Chemotherapy and Pharmacology vol:68 issue:5 pages:1347-1353
Abstract: Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents. A phase I-II study was designed to determine the recommended dose (RD) and the anti-tumour effect of a prolonged administration of elacytarabine, the elaidic ester of cytarabine, in patients with refractory/resistant recurrent ovarian cancer.
ISSN: 0344-5704
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science